NVDL:OTO-Novadel Pharma Inc (USD)

ETF | Others | OTC Pink

Last Closing

USD 67.48

Change

0.00 (0.00)%

Market Cap

USD 0.98M

Volume

0.02B

Analyst Target

USD 1.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NovaDel Pharma Inc. is a pharmaceutical Company, which develops oral spray formulations for a range of marketed pharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
IBIT iShares Bitcoin Trust

-1.94 (-3.54%)

USD 53.00B
QQQM Invesco NASDAQ 100 ETF

+1.74 (+0.81%)

USD 38.88B
JEPQ JPMorgan Nasdaq Equity Premium..

+0.47 (+0.82%)

USD 20.37B
ACWI iShares MSCI ACWI ETF

+0.73 (+0.62%)

USD 19.97B
CGABL The Carlyle Group Inc. 4.625% ..

-0.36 (-1.99%)

USD 16.14B
TSLL Direxion Shares ETF Trust - Di..

+1.37 (+4.49%)

USD 5.32B
TBIL Rbb Fund Inc - Us Treasury 3 M..

N/A

USD 4.54B
ETHA iShares Ethereum Trust ETF

-0.34 (-1.30%)

USD 3.54B
USCL iShares Climate Conscious & Tr..

+0.42 (+0.59%)

USD 2.64B
MSTX Defiance Daily Target 1.75x Lo..

-14.02 (-17.39%)

USD 2.16B

ETFs Containing NVDL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 351.87% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 351.87% 100% F 98% N/A
Trailing 12 Months  
Capital Gain 313.99% 98% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 313.99% 98% N/A 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 155.83% 98% N/A 94% A
Dividend Return 155.83% 98% N/A 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 190.00% 3% F 13% F
Risk Adjusted Return 82.01% 88% B+ 92% A
Market Capitalization 0.98M 98% N/A 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative earnings

The company had negative total earnings in the most recent four quarters.